Emergent BioSolutions (EBS) AGM 2026 summary

Opening remarks and agenda

• Meeting called to order with board members and executive team introduced, highlighting progress on a multi-year turnaround plan and improved financial position in 2025.

• Agenda included director elections, ratification of auditors, advisory vote on executive compensation, and amendment to the stock incentive plan.

Financial performance review

• Achieved strong adjusted EBITDA of $205 million, improved operating margins, increased cash flow, and reduced debt leverage in 2025.

• Improved cash balance by $100 million and reduced debt by $110 million.

• Secured multiple medical countermeasure contracts and expanded the naloxone portfolio.

Board and executive committee updates

• Four directors nominated for election to serve until the 2029 annual meeting.

• Board and executive team reaffirmed commitment to transformation and long-term growth.